Reslizumab Works Best in Late-Onset Eosinophilic Asthma – Medscape


Medscape

Reslizumab Works Best in Late-Onset Eosinophilic Asthma
Medscape
AMSTERDAM — In patients with late-onset asthma who have elevated blood eosinophils, the anti-interleukin 5 (IL-5) antibody reslizumab can reduce exacerbations by 75% compared with placebo, according to a new analysis of data from two phase 3 trials …
Teva Presents New Reslizumab Data at European Respiratory Society (ERS Business Wire (press release)

all 9 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.